The Importance of Pectoralis Minor Syndrome in Hemiplegic Shoulder Pain
Launched by ISTANBUL UNIVERSITY - CERRAHPASA · Sep 25, 2024
Trial Information
Current as of July 12, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called hemiplegic shoulder pain, which is common in people who have had a stroke. This type of pain often happens because of muscle weakness or problems with the joints and nerves. The researchers are particularly interested in a muscle called the pectoralis minor, as they believe it may play a significant role in causing this shoulder pain. By understanding how this muscle affects pain levels, the study aims to improve treatment and rehabilitation strategies for those experiencing hemiplegic shoulder pain.
To participate in the trial, individuals must be between 65 and 74 years old, have developed spastic hemiplegia (which means one side of their body is weak) due to a stroke, and experience shoulder pain on the affected side. However, certain conditions would exclude someone from participating, such as being unable to communicate, having severe sensitivities, or having undergone certain surgeries. Participants can expect to contribute to important research that may lead to better management of shoulder pain in stroke patients, helping healthcare providers offer more effective treatment options in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Development of spastic hemiplegia due to stroke
- • Presence of shoulder pain on the hemiplegic side
- Exclusion Criteria:
- • Lack of medical stability
- • Inability to communicate verbally
- • History of severe sensitivity to lidocaine injections
- • Surgical history related to the hemiplegic shoulder
- • Presence of a prosthesis in the hemiplegic shoulder
- • Malignancy in the hemiplegic shoulder
- • Severe psychiatric illness
- • History of injections to the hemiplegic shoulder within the last 6 months
- • Pregnancy
- • History of inflammatory rheumatic disease
About Istanbul University Cerrahpasa
Istanbul University - Cerrahpasa is a prestigious academic institution renowned for its commitment to advancing medical research and education. With a focus on innovative clinical trials, the university harnesses cutting-edge methodologies to address pressing health challenges. Its collaborative environment fosters interdisciplinary research, enabling the development of effective therapeutic strategies and enhancing patient care. The institution's dedication to ethical standards and patient safety underscores its reputation as a leader in clinical research within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported